上海药明生物技术有限公司 Wuxi Biologics
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development 2024-10-28 17:00
WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year 2024-10-16 20:00
WuXi Biologics Included in Hang Seng ESG 50 Index 2024-09-23 17:30
WuXi Biologics Reports Solid 2024 Interim Results 2024-08-21 23:46
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers 2024-08-08 16:00
WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics 2024-08-01 15:00
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year 2024-07-10 13:30
WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment 2024-04-30 10:55
WuXi Biologics Reports Solid 2023 Annual Results 2024-03-26 21:53
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment 2024-03-05 21:00
WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics 2024-02-21 18:00
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland 2024-01-31 17:31
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect 2024-01-25 08:30
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™ 2024-01-17 08:30
WuXi Biologics to Increase Manufacturing Capacity in Massachusetts 2024-01-08 17:52
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index 2023-12-12 17:00
WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating 2023-12-08 17:40
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale 2023-11-22 13:21
WuXi Biologics Receives AAA MSCI ESG Rating 2023-11-08 08:30
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality 2023-10-17 08:30
1 2 3 4 5 9